TSCAN THERAPEUTICS, INC.

(TCRX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

TScan Therapeutics : Cowen Initiates Coverage on TScan Therapeutics With Outperform Rating

08/13/2021 | 06:18am EDT


© MT Newswires 2021
All news about TSCAN THERAPEUTICS, INC.
05/19TScan Therapeutics Presents Preclinical Data at the American Society of Gene and Cell T..
GL
05/19TScan Therapeutics Presents Preclinical Data at the American Society of Gene and Cell T..
AQ
05/17TScan Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
GL
05/17TScan Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
AQ
05/12TSCAN THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a..
AQ
05/12TScan Therapeutics to Host Virtual KOL Event to Discuss its Solid Tumor Program Strateg..
GL
05/12TScan Therapeutics to Host Virtual KOL Event to Discuss its Solid Tumor Program Strateg..
AQ
05/10HC Wainwright Lowers TScan Therapeutics Price Target to $15 From $21, Maintains Buy Rat..
MT
05/09TScan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31,..
CI
05/09TScan Therapeutics Reports First Quarter 2022 Financial Results and Upcoming Anticipate..
GL
More news
Analyst Recommendations on TSCAN THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 12,8 M - -
Net income 2022 -71,1 M - -
Net cash 2022 77,4 M - -
P/E ratio 2022 -0,94x
Yield 2022 -
Capitalization 69,0 M 69,0 M -
EV / Sales 2022 -0,66x
EV / Sales 2023 -1,56x
Nbr of Employees 105
Free-Float 56,8%
Chart TSCAN THERAPEUTICS, INC.
Duration : Period :
TScan Therapeutics, Inc. Technical Analysis Chart | TCRX | US89854M1018 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 2,88 $
Average target price 14,00 $
Spread / Average Target 386%
EPS Revisions
Managers and Directors
David P. Southwell President, Chief Executive Officer & Director
Brian Michael Silver Chief Financial Officer & Treasurer
Timothy Joseph Barberich Chairman
Gavin MacBeath Chief Scientific Officer
Jim Murray Vice President-Clinical
Sector and Competitors
1st jan.Capi. (M$)
TSCAN THERAPEUTICS, INC.-36.00%69
MODERNA, INC.-48.00%52 528
LONZA GROUP AG-27.13%42 896
IQVIA HOLDINGS INC.-28.41%38 232
SEAGEN INC.-13.67%24 569
ICON PUBLIC LIMITED COMPANY-30.17%17 581